Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model
Biopharmaceutics & Drug Disposition · 2023-08 · 44 (4) · 344-347
DOI: 10.1002/bdd.2369 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biopharmaceutics & Drug Disposition, online erschienen am 22.06.2023. Verfasst von Joseph A Grillo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Labeling and Health Communication, Office of Clinical Pharmacology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP3A Inhibitors, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 7 Literaturangaben.
Abstract (Originalsprache)
Today real word data (RWD) are playing a greater role in informing health care decisions. A physiologically based pharmacokinetic model (PBPK) and observed exposure–risk relationship predicted an increased bleeding risk induced by rivaroxaban (RXB) in patients with mild to moderate chronic kidney disease (CKD) taking concomitant medications that are combined Pgp‐CYP3A inhibitors. In this commentary, we explore the potential use of RWD to assess the clinical consequence of this complex drug–drug interaction predicted from PBPK. This is a retrospective, case control, pilot study using a RWD dataset of 896,728 patients with mild to moderate chronic kidney disease and rivaroxaban use that was refined based upon combined Pgp‐CYP3A inhibitor exposure and report of drug‐induced bleeding (DIB). The odds ratio of patients with mild to moderate chronic kidney disease taking rivaroxaban with or without concurrent Pgp‐CYP3A inhibitor use having a DIB was calculated. The odds ratio for DIB was 2.04 (CI 95 1.82, 2.3; p < 0.001) suggesting an approximate doubling of bleeding risk which is consistent with the rivaroxaban exposure changes predicted by the published PBPK model and observed exposure–risk relationship. This exploratory analysis demonstrated the potential utility of RWD to assess model‐based predictions as part of a drugs life cycle management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Labeling and Health Communication, Office of Clinical Pharmacology, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.
- Quantitative Sciences, Global Health - Integrated Development, Bill & Melinda Gates Foundation, University of Washington, Seattle, Washington, USA.
- Bill & Melinda Gates Foundation, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Joseph A Grillo
Zitieren
APA
Grillo, J. A., McNair, D., & Zhao, P. (2023). Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model. Biopharmaceutics & Drug Disposition, 44(4), 344-347. https://doi.org/10.1002/bdd.2369
Vancouver
Grillo JA, McNair D, Zhao P. Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model. Biopharmaceutics & Drug Disposition. 2023;44(4):344-347. doi:10.1002/bdd.2369
BibTeX
@article{Grillo2023,
author = {Grillo, Joseph A and McNair, Douglas and Zhao, Ping},
title = {Coming full circle: The potential utility of real‐world evidence to discern predictions from a physiologically based pharmacokinetic model},
journal = {Biopharmaceutics & Drug Disposition},
year = {2023},
volume = {44},
number = {4},
pages = {344--347},
doi = {10.1002/bdd.2369}
}
EUVIMED